🧪
hypothesis

NLRP3 inflammasome amplification across AD and PD proteinopathy

Hypothesis

NLRP3 inflammasome amplification across AD and PD proteinopathy

Shared mechanism across AD, PD: Misfolded protein stress activates microglial NLRP3; IL-1 beta and inflammasome signaling then amplify amyloid/tau pathology in AD and alpha-synuclein pathology with dopaminergic injury in PD, creating a s.
🧬 NLRP3🩺 multi🎯 Composite 80%💱 $0.53▲2.5%validated
neurodegeneration
EvidenceStrong (88%)📖 27 cit🗣 1 debates✓ 9 support✗ 1 oppose
✓ All Quality Gates Passed
Mechanistic 0.85 (15%) Evidence 0.79 (15%) Novelty 0.82 (12%) Feasibility 0.68 (12%) Impact 0.86 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.60 (8%) 0.800 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite80%

🧪 Overview

Shared mechanism across AD, PD: Misfolded protein stress activates microglial NLRP3; IL-1 beta and inflammasome signaling then amplify amyloid/tau pathology in AD and alpha-synuclein pathology with dopaminergic injury in PD, creating a shared inflammatory feed-forward loop.

Falsifiable prediction: Selective NLRP3 inhibition should reduce ASC speck formation and IL-1 beta release by at least 50%, and secondarily lower tau/alpha-synuclein seeded aggregation by at least 20% in AD and PD co-culture models.

Proposed experiment: Treat APP/PS1-tau microglia-neuron co-cultures and alpha-synuclein PD co-cultures with a selective NLRP3 inhibitor, NLRP3 knockout, and inactive analog; quantify ASC specks, caspase-1, IL-1 beta, p-tau, alpha-synuclein seeds, and neuronal survival.

Cross-disease confidence rationale: Direct AD mouse evidence plus PD alpha-synuclein inflammasome inhibition evidence.

Internal SciDEX support: SciDEX support query found 96 matching hypotheses across 8 disease labels, including 96 with debate_count > 0.

Generated by task ffd81f3a-7f04-4db1-8547-1778ce030e89 as a cross-disease mechanism synthesis, not a single-disease hypothesis renamed as multi-disease.

🧬 Mechanism

🔗 Mechanism from KG for NLRP3

Auto-built from this analysis's top knowledge-graph edges.

graph TD
    alpha_synuclein_fibrils["alpha-synuclein fibrils"] -->|activates| NLRP3_Inflammasome["NLRP3 Inflammasome"]
    NLRP3["NLRP3"] -->|cross disease mech| AD["AD"]
    NLRP3_1["NLRP3"] -->|cross disease mech| PD["PD"]
    h_cross_synth_nlrp3_infla["h-cross-synth-nlrp3-inflammasome"] -->|proposes shared me| NLRP3_2["NLRP3"]
    MCC950__NLRP3_inhibitor_["MCC950 (NLRP3 inhibitor)"] -.->|inhibits| neuroinflammation["neuroinflammation"]
    style alpha_synuclein_fibrils fill:#4fc3f7,stroke:#333,color:#000
    style NLRP3_Inflammasome fill:#ce93d8,stroke:#333,color:#000
    style NLRP3 fill:#4fc3f7,stroke:#333,color:#000
    style AD fill:#ef5350,stroke:#333,color:#000
    style NLRP3_1 fill:#4fc3f7,stroke:#333,color:#000
    style PD fill:#ef5350,stroke:#333,color:#000
    style h_cross_synth_nlrp3_infla fill:#4fc3f7,stroke:#333,color:#000
    style NLRP3_2 fill:#4fc3f7,stroke:#333,color:#000
    style MCC950__NLRP3_inhibitor_ fill:#4fc3f7,stroke:#333,color:#000
    style neuroinflammation fill:#4fc3f7,stroke:#333,color:#000

⚖️ Evidence

⚖️ Evidence Matrix9 supports0 contradicts
Supports
NLRP3 is activated in AD and contributes to pathology in APP/PS1 mice.
2013PMID:23254930high
Supports
NLRP3 inflammasome activation drives tau pathology.
2019PMID:31748742high
Supports
Inflammasome inhibition prevents alpha-synuclein pathology and dopaminergic neurodegeneration.
2018PMID:30381407high
Supports
Autophagy-NLRP3 interactions span AD and PD.
2023PMID:36262883medium
Supports
NLRP3-dependent caspase-1 activation causes maturation and release of IL-1beta from microglia into the extracellular milieu.
PMID:28940479
Supports
NLRP3-dependent caspase-1 activation causes maturation and release of IL-1beta from microglia into the extracellular milieu.
PMID:39381137
Supports
NLRP3 inflammasome activation in microglia creates a feed-forward loop wherein IL-1beta-induced protein pathology further activates NLRP3, sustaining chronic neuroinflammation.
PMID:31748742
Supports
NLRP3 inflammasome activation in microglia creates a feed-forward loop wherein IL-1beta-induced protein pathology further activates NLRP3, sustaining chronic neuroinflammation.
PMID:37917301
Supports
NLRP3 inflammasome activation in microglia creates a feed-forward loop wherein IL-1beta-induced protein pathology further activates NLRP3, sustaining chronic neuroinflammation.
PMID:37541353
📖 Linked Papers (5)Export BibTeX ↗
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice.
Science translational medicine (2018) · PubMed:30381407 ↗
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
Interaction between autophagy and the NLRP3 inflammasome in Alzheimer's and Parkinson's disease.
Frontiers in aging neuroscience (2023) · PubMed:36262883 ↗
No figures
NLRP3 inflammasome activation drives tau pathology.
Nature (2019) · PubMed:31748742 ↗
No figures
NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice.
Nature (2013) · PubMed:23254930 ↗
No figures
NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice.
Nature (2013) · PubMed:23254930 ↗
No figures

🏥 Translation

🧬 3D Protein Structure — NLRP3

🧬 PDB 7PZC Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for NLRP3 →

No DepMap CRISPR Chronos data found for NLRP3.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0004
Events (7d)
1
Price History
▲2.5%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations1 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
Selective NLRP3 inhibition should reduce ASC speck formation and IL-1 beta release by at least 50%, and secondarily lower tau/alpha-synuclein seeded aggregation by at least 20% in AD and PD co-cultureIf this mechanism is real, then Selective NLRP3 inhibition should reduce ASC speck formation and IL-1 beta release by at least 50%, and secondarily lower tau/al— no observation —pending0.79
🔮 Falsifiable Predictions (1)
pendingconf 79%
Selective NLRP3 inhibition should reduce ASC speck formation and IL-1 beta release by at least 50%, and secondarily lower tau/alpha-synuclein seeded aggregation by at least 20% in AD and PD co-culture models.
Predicted outcome: If this mechanism is real, then Selective NLRP3 inhibition should reduce ASC speck formation and IL-1 beta release by at least 50%, and secondarily lo
Falsification: Falsified if the experiment produces results more than 20% below the predicted effect size
View on SciDEX ↗